Septerna's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding. Read why SEPN stock ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

The U.S. stock market rallied. The S&P 500 climbed 1.5% Monday for one of its best days since the summer and added to its ...

Broadcom’s stock surged 11.10% to close at $377.96, reaching an intraday high of $382 and a low of $347.66. The stock’s ...

Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

Tia here with news that a trial of the pill form of the GLP-1 drug semaglutide has failed to delay Alzheimer's progression in ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk shares sliding on latest drug trial and how to treat the stock at ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Chip stocks and other big technology shares rallied Monday, extending Friday’s gains. A positive talk between President Trump and Chinese President Xi also boosted markets. Plus: Novo Nordisk stock ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...